High Proportions of Patients With Advanced HIV Are Antiretroviral Therapy Experienced: Hospitalization Outcomes From 2 Sub-Saharan African Sites

被引:54
|
作者
Ousley, Janet [1 ]
Niyibizi, Aline Aurore [1 ]
Wanjala, Stephen [1 ]
Vandenbulcke, Alexandra [1 ]
Kirubi, Beatrice [1 ]
Omwoyo, Willis [1 ]
Price, Janthimala [1 ]
Salumu, Leon [1 ]
Szumilin, Elisabeth [1 ]
Spiers, Sofie [2 ]
van Cutsem, Gilles [2 ]
Mashako, Maria [2 ]
Mangana, Freddy [2 ]
Moudarichirou, Ramzia [2 ]
Harrison, Rebecca [2 ]
Kalwangila, Tony [2 ]
Lumowo, Gisele [2 ]
Lambert, Vincent [2 ]
Maman, David [3 ]
机构
[1] Medecins Sans Frontieres, Paris, France
[2] Medecins Sans Frontieres, Brussels, Belgium
[3] Epicentre, Paris, France
基金
比尔及梅琳达.盖茨基金会;
关键词
Kenya; Democratic Republic of Congo; treatment failure; LIFE EXPECTANCY; MORTALITY; DISEASE; DEATH; ERA;
D O I
10.1093/cid/ciy103
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Human immunodeficiency virus (HIV) remains an important cause of hospitalization and death in low- and middle- income countries. Yet morbidity and in-hospital mortality patterns remain poorly characterized, with prior antiretroviral therapy (ART) exposure and treatment failure status largely unknown. Methods. We studied HIV-infected inpatients aged >= 13 years from cohorts in Kenya and the Democratic Republic of Congo (DRC), assessing clinical and demographic characteristics and hospitalization outcomes. Kenyan inpatients were prospectively enrolled during hospitalization; identical retrospective data were extracted for Congolese patients meeting the study criteria using routine medical information. Results. Among 338 HIV-infected patients in Kenya and 411 in DRC, 83.7% (95% confidence interval [CI], 79.4%-87.3%) and 97.3% (95% CI, 95.2%-98.5%), were admitted with advanced disease (defined as CD4 < 200 cells/mu L or World Health Organization stage 3/4 illness). Among inpatients with advanced HIV, 35.4% and 21.7% were ART-naive at admission. Patients under care had a median time of 44.1 (interquartile range [IQR], 18.4-90.5) months and 55.9 (IQR, 28.1-99.6) months on treatment; 17.2% (95% CI, 13.5%-21.6%) and 29.6% (95% CI, 25.4%-34.3%) died, 25.9% (95% CI, 16.0%-39.0%) and 22.5% (95% CI, 15.8%-31.0%) of these within 48 hours. Conclusions. Across 2 diverse clinical contexts in sub-Saharan Africa, advanced HIV inpatients were frequently admitted with low CD4 counts, often failing first-line ART. Earlier identification of treatment failure and rapid switching to second-line ART are needed.
引用
收藏
页码:S126 / S131
页数:6
相关论文
共 50 条
  • [31] Antiretroviral therapy uptake and coverage in four HIV community cohort studies in sub-Saharan Africa
    Wringe, Alison
    Floyd, Sian
    Kazooba, Patrick
    Mushati, Phyllis
    Baisley, Kathy
    Urassa, Mark
    Molesworth, Anna
    Schumacher, Christina
    Todd, Jim
    Zaba, Basia
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2012, 17 (08) : e38 - e48
  • [32] Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa
    Kroeze, Stefanie
    Ondoa, Pascale
    Kityo, Cissy M.
    Siwale, Margaret
    Akanmu, Sulaimon
    Wellington, Maureen
    de Jager, Marleen
    Ive, Prudence
    Mandaliya, Kishor
    Stevens, Wendy
    Boender, T. Sonia
    de Pundert, Marieke E.
    Sigaloff, Kim C. E.
    Reiss, Peter
    Wit, Ferdinand W. N. M.
    de Wit, Tobias F. Rinke
    Hamers, Raph L.
    AIDS, 2018, 32 (08) : 1043 - 1051
  • [33] Commentary: Early antiretroviral therapy for HIV infection in sub-Saharan Africa, a challenging new step
    Christian Laurent
    Journal of Public Health Policy, 2010, 31 : 401 - 406
  • [34] Adults Receiving HIV Care Before the Start of Antiretroviral Therapy in Sub-Saharan Africa: Patient Outcomes and Associated Risk Factors
    Bastard, Mathieu
    Nicolay, Nathalie
    Szumilin, Elisabeth
    Balkan, Suna
    Poulet, Elisabeth
    Pujades-Rodriguez, Mar
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 64 (05) : 455 - 463
  • [35] Development of peripheral neuropathy after stavudine-based antiretroviral therapy in HIV positive (HIV+) patients in sub-Saharan Africa
    Peters, Katherine B.
    Nakasujja, Noeline
    Robertson, Kevin R.
    Liner, Jeff
    Skolasky, Richard L.
    Basenero, Apollo
    Kambugu, Andrew
    Katabira, Elly
    Musisi, Seggane
    Ronald, Allan
    Clifford, David
    Sacktor, Ned
    ANNALS OF NEUROLOGY, 2007, 62 : S77 - S77
  • [36] Screening for active tuberculosis among patients accessing antiretroviral therapy in sub-Saharan Africa
    Lawn, Stephen D.
    Kranzer, Katharina
    Edwards, David J.
    Wood, Robin
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2009, 13 (09) : 1186 - 1187
  • [37] HIV knowledge trends during an era of rapid antiretroviral therapy scale-up: an analysis of 33 sub-Saharan African countries
    Chan, Brian T.
    Tsai, Alexander C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 (07)
  • [38] Standard of care in advanced HIV disease: review of HIV treatment guidelines in six sub-Saharan African countries
    Scheier, Thomas C.
    Youssouf, Nabila
    Mosepele, Mosepele
    Kanyama, Cecilia
    Adekanmbi, Olukemi
    Lakoh, Sulaiman
    Muzoora, Conrad K.
    Meintjes, Graeme
    Mertz, Dominik
    Eikelboom, John W.
    Wasserman, Sean
    AIDS RESEARCH AND THERAPY, 2023, 20 (01)
  • [39] Standard of care in advanced HIV disease: review of HIV treatment guidelines in six sub-Saharan African countries
    Thomas C. Scheier
    Nabila Youssouf
    Mosepele Mosepele
    Cecilia Kanyama
    Olukemi Adekanmbi
    Sulaiman Lakoh
    Conrad K. Muzoora
    Graeme Meintjes
    Dominik Mertz
    John W. Eikelboom
    Sean Wasserman
    AIDS Research and Therapy, 20
  • [40] HIV-1 drug resistance in antiretroviral-naive patients in sub-Saharan Africa
    Hamers, Raph L.
    Sigaloff, Kim C. E.
    Kityo, Cissy
    Mugyenyi, Peter
    de Wit, Tobias F. Rinke
    LANCET INFECTIOUS DISEASES, 2013, 13 (03): : 196 - 197